Perceptive Advisors Lowers stake in Xencor Inc (XNCR)

Xencor Inc (XNCR) : Perceptive Advisors reduced its stake in Xencor Inc by 15.25% during the most recent quarter end. The investment management company now holds a total of 1,529,574 shares of Xencor Inc which is valued at $34,033,022 after selling 275,210 shares in Xencor Inc , the firm said in a disclosure report filed with the SEC on Aug 11, 2016.Xencor Inc makes up approximately 2.49% of Perceptive Advisors’s portfolio.

Other Hedge Funds, Including , Rhumbline Advisers boosted its stake in XNCR in the latest quarter, The investment management firm added 7,493 additional shares and now holds a total of 34,804 shares of Xencor Inc which is valued at $774,389.Vanguard Group Inc boosted its stake in XNCR in the latest quarter, The investment management firm added 197,814 additional shares and now holds a total of 1,343,701 shares of Xencor Inc which is valued at $29,897,347.Victory Capital Management Inc boosted its stake in XNCR in the latest quarter, The investment management firm added 30 additional shares and now holds a total of 1,447 shares of Xencor Inc which is valued at $31,588.Geneva Advisors reduced its stake in XNCR by selling 6,200 shares or 8.18% in the most recent quarter. The Hedge Fund company now holds 69,555 shares of XNCR which is valued at $1,518,386. Xencor Inc makes up approx 0.03% of Geneva Advisors’s portfolio. Great West Life Assurance Co Can added XNCR to its portfolio by purchasing 5,621 company shares during the most recent quarter which is valued at $118,940.

Xencor Inc closed down -0.09 points or -0.41% at $21.67 with 3,08,810 shares getting traded on Tuesday. Post opening the session at $21.76, the shares hit an intraday low of $21.47 and an intraday high of $21.8 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

Xencor Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. The Company uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases cancer and other conditions. The Company’s product pipeline includes three lead XmAb-engineered antibodies which include XmAb5871 XmAb7195 and XmAb5574/MOR208. XmAb5871 is indicated for the treatment of moderate-to-severe rheumatoid arthritis. XmAb7195 is the Company’s wholly owned program being developed for the treatment of severe asthma and allergic diseases. XmAb5574/MOR208 is being developed for the treatment of blood-based cancers.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *